3rd Dec 2008 11:59
|
For immediate release |
3 December 2008 |
ABCAM PLC
("Abcam" or "the Company")
ABCAM PLC SHARE INCENTIVE PLAN
Directors' Dealings
On 7 November 2008 Abcam announced that as a result of transactions on 6 November 2008 by the Abcam plc Share Incentive Plan -"the Plan" - (an HMRC approved all employee share purchase plan adopted by the Company's shareholders at the Company's AGM on 3 November 2008), Jonathan Milner, Jeff Iliffe and Jim Warwick, Executive Directors of the Company, had each been awarded 649 "Free shares". The beneficial ownership of these shares will pass to the Executive Directors on 6 November 2011 subject to their continued employment with Abcam plc.
The final dividend of 4.56 pence per share which was approved at the AGM was paid on 28 November 2008. Pursuant to the terms of the Plan, on 2 December 2008, the dividend paid on the "Free shares" granted to the Executive Directors as detailed above was used to purchase additional shares at 475p each to be held on behalf of the Executive Directors in the Abcam plc Share Incentive Plan. These shares are as detailed below:
|
Dividend shares purchased |
No of shares held in the Plan on 2 December 2008 Including the dividend shares |
|
|
Jeff Iliffe |
6 |
1,273 |
|
Jonathan Milner |
6 |
1,273 |
|
Jim Warwick |
6 |
1,273 |
For further information please contact:
|
Abcam
|
+ 44 (0) 1223 696000
|
|
Jonathan Milner, Chief Executive Officer
|
|
|
Jeff Iliffe, Chief Financial Officer
www.abcam.com
|
|
|
|
|
|
Numis Securities
|
+ 44 (0) 20 7776 1500
|
|
Nominated Adviser - Michael Meade, Nick Westlake
Corporate Broking - James Black
|
|
|
|
|
|
Buchanan Communications
|
+ 44 (0) 20 7466 5000
|
|
Mark Court / Mary-Jane Johnson
|
|
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 47,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs over 200 staff in its three operating companies.
Related Shares:
ABC.L